![]() |
|
|
Vol. 19, Issue 10, 4086-4098, October 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

*Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland; and
Novartis Institutes for Biomedical Research Basel, Neuroscience Research, Novartis Pharma AG, CH-4002 Basel, Switzerland
Submitted May 6, 2008;
Revised July 3, 2008;
Accepted July 8, 2008
Monitoring Editor: Reid Gilmore
| ABSTRACT |
|---|
|
|
|---|
-glucosidase II. Addition of 1–4 N-glycans progressively enhanced the dissociation rate from BiP and reduced the propensity of newly synthesized BACE to enter aberrant soluble and insoluble aggregates. Finally, inhibition of the proteasome increased the yield of active BACE. This shows that active protein normally targeted for destruction can be diverted for secretion, as if for BACE the quality control system would be acting too stringently in the ER lumen, thus causing loss of functional polypeptides. | INTRODUCTION |
|---|
|
|
|---|
Systematic studies aiming at understanding mechanisms regulating protein biogenesis in living cells are rare and rely on a very short list of select model substrates (Pearse et al., 2008
and references therein). Characterization of the mechanisms that regulate protein folding, quality control, and disposal from the ER lumen is crucial because defects in polypeptide maturation are often linked to highly debilitating conformational diseases (Aridor, 2007
). The capacity to intervene in protein biogenesis will lead to development of therapeutic approaches aiming at delaying the progressive worsening of disease conditions or even at reverting disease phenotypes by using chemical and pharmacological chaperones that enhance protein folding or delay degradation of intermediates of protein folding programs (Molinari, 2007
and references therein). It will also facilitate more efficient and rentable production of recombinant proteins to be used in the clinics or in the industry (Baldi et al., 2007
).
Here we performed a thorough analysis of the fate of a disease-regulating glycoprotein, the soluble form of human BACE (BACEs, see Figure 1A). BACEs was selected as model substrate because it can be produced in Escherichia coli and refolded in active form from inclusion bodies (Hong et al., 2000
; Sardana et al., 2004
; Shimizu et al., 2008
). In principle therefore, this protein can attain an active form independent of N-glycosylation. Several variants of BACEs with 4, 3, 2, 1, or 0 N-linked glycans were ectopically expressed in human cells. We studied the dependency of the glycosylation state for parameters such as secretion rate and efficiency, chaperone use, formation of byproducts of the folding program, enzymatic activity, and enhancement of production yield upon manipulation of the ER folding and degradation capacity.
|
| MATERIALS AND METHODS |
|---|
|
|
|---|
MEM, respectively, supplemented with 10% FBS. Cells were transiently transfected with Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer.
Radiolabeling and Immunoprecipitations
Eighteen hours after transfection, cells were starved for 15 min in Met/Cys free medium, pulsed for 10 min with 50 µCi [35S]Met/Cys in 1 ml starvation medium/dish, and chased for the indicated times with DMEM supplemented with 5 mM cold Met/Cys. Extracellular medium was centrifuged (10 min at 10,000 x g) before immunoisolation of BACEs. Postnuclear supernatants (PNS) were prepared by solubilization of cells in 800 µl/dish ice-cold 2% CHAPS in HEPES-buffered saline (HBS), pH 6.8, containing 20 mM N-ethylmaleimide, protease inhibitors, and 10 U/dish of apyrase for BiP immunoprecipitations. CHAPS-insoluble material was separated by 10-min centrifugation at 10,000 x g. CHAPS-insoluble material was solubilized by boiling in 1% SDS and subsequent addition of 10 volumes of 1% Triton X-100. Immunoprecipitations were performed by adding protein A beads (Sigma; 1:10, w/v swollen in HBS) and the selected antibody to extracellular medium or cell extracts. Incubations were 1–4 h at 4°C. The immunoprecipitates were extensively washed, three times, with 0.5% CHAPS in HBS and resuspended in sample buffer for SDS-PAGE. Relevant bands were quantified by ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Gels were also exposed to BioMax (Eastman-Kodak, Rochester, NY) films and scanned with an AGFA scanner (Mortsel, Belgium).
Endoglycosidase H Treatment
Secreted BACEs1 was immunoisolated and denatured in 0.5% SDS, 40 mM DTT and incubated for 2 h with recombinant endoglycosidase H (EndoH, New England BioLabs, Beverly, MA) at 37°C.
Immunoblotting
Forty hours after transfection cells were grown in the absence/presence of 9 µM PS-341 (Velcade, kind gift of R. Sitia, Milan) for 150 min. The extracellular media were collected, separated in reducing SDS-PAGE, and transferred onto PVDF membranes. Membranes were decorated with a monoclonal anti-BACE or a polyclonal anti-ubiquitin (1:1000). Secondary antibodies were HRP-conjugated anti-mouse IgG (1:5000) and HRP-conjugated anti-rabbit IgG (1:5000). Detection and protein amount analysis were performed with the ECL-Plus detection system (Amersham GE Healthcare, Waukesha, WI) and with the LAS4000 software.
BACE Activity Assay
Extracellular medium (10 µl) was directly incubated for 30 min in a reaction buffer (20 mM acetic acid, pH 4.5, 0.01% CHAPS, and 0.01% TOP BLOCK to improve BACEs solubility during the activity essay) containing 1 µMfin ALEXA-substrate. Activity was measured in Corning 96-well microplates (Corning Glass Works, Corning, NY) using the SPECTRAmax GEMINIXPS spectrofluorometer (Molecular Devices). The increase in fluorescence upon substrate hydrolysis was measured (every 50 s) with the SoftMax Prosoftware. Relative activities represent the slope of the straight line obtained by plotting the increase in fluorescence over time.
| RESULTS |
|---|
|
|
|---|
The amount of labeled BACEs immunoisolated from cell lysates decreased (Figure 1, B–F, intracellular) as a function of protein secretion with progression of the chase (Figure 1, B–F, secreted). This showed that for all glycosylation mutants, a variable fraction of the newly synthesized, labeled protein was secreted in the extracellular media.
The amount of detergent-soluble labeled BACEs0 retained intracellularly decreased to
25% of the initial amount after 240 min and to
10% after 480 min of chase (Figure 1B, intracellular). The amount of labeled BACEs0 immunoisolated from the cell culture media did not exceed the 5% of the initial synthesized pool of protein (Figure 1B, secreted). Thus, secretion of nonglycosylated BACEs0 was very inefficient; the vast majority of newly synthesized BACEs0 underwent degradation or entered in detergent-insoluble aggregates (see below).
The mono- and di-glycosylated BACEs variants disappeared with faster kinetics from the intracellular fractions (Figures 1, C–D, intracellular). Secretion of BACEs1 (38%, Figure 1C, secreted) and of BACEs2 (44%, Figure 1D, secreted) was much more efficient compared with secretion of the nonglycosylated version of the model protein (5%, Figure 1B, secreted).
The more extensively glycosylated forms of BACEs (BACEs3, Figure 1E, and BACEs4, Figure 1F) disappeared even faster from the detergent lysates and were secreted with the highest efficiency (
60%, Figure 1, E and F).
These data demonstrated the existence of a direct correlation between the extent of BACEs glycosylation and the efficiency of secretion.
A Direct Correlation between Extent of BACEs Glycosylation and Secretion Kinetics
The data for the secretion rates and secretion efficiencies are summarized for the five glycosylation mutants in Figure 1G. These data confirm the direct correlation existing between the extent of BACEs glycosylation, the secretion efficiency and the secretion rate (Figure 1G). Secretion of the nonglycosylated mutant (BACEs0) was very slow and inefficient. BACEs1 and BACEs2 had similar secretion kinetics, with a t50 (time of half-maximal secretion) of
90 min. The more extensively glycosylated BACEs3 and BACEs4 showed a t50 of
60 min.
A Direct Correlation between Extent of BACEs Glycosylation and Rate of Acquisition of a DTT-resistant Conformation
As a rule, newly synthesized polypeptides are released from the ER only upon attainment of the native structure (Ellgaard et al., 1999
). Unfortunately, conformational antibodies discriminating native from nonnative BACEs are not available. Thus, to confirm that kinetics and extent of secretion were dependent on the acquisition of the native structure, we monitored the rate of generation of DTT-resistant disulfides in the five glycosylation mutants. In most folded proteins, intramolecular disulfide bonds are solvent inaccessible and are not reduced by moderate DTT concentrations (Thornton, 1981
).
At the end of each chase time shown in Figure 2 and before lysis, cells were incubated for 5 min on ice in a medium containing 5 mM DTT. Cell incubation with this concentration of DTT readily reduces nonnative, solvent exposed, intramolecular disulfides without affecting native disulfides (Tatu et al., 1993
). The labeled BACEs mutants were immunoisolated from PNS, and the proteins were separated under nonreducing conditions. Disulfide bonds in nonnative conformers were fully reduced by the DTT treatment on ice. Consequently, nonnative conformers showed slower electrophoretic mobility (
sens in Figure 2) when compared with native ones. In the latter, preservation of covalent bonds linking cysteines resulted in faster electrophoretic mobility (
res in Figure 2). The DTT-sensitive and the DTT-resistant labeled polypeptide bands were quantified and the ratio DTT-resistant:DTT-sensitive was plotted (Figure 2).
|
80% of the intracellular BACEs0 was fully reduced upon exposure of cells to DTT. Addition of 1, 2, 3, and 4 N-glycans progressively accelerated the formation of DTT-resistant conformers that reached the 37, 62, 86, and 98% after the 80 min of chase shown in Figure 2, B–E, respectively. As discussed above, the fraction of labeled, DTT-resistant form of the proteins eventually decreased during the chase because the native (and DTT-resistant) conformers are rapidly secreted in the extracellular media (Figure 1).
An Inverse Correlation between Number of Glycans and Persistence of BiP Binding
Next, we assessed whether BACEs variants did associate with BiP, an abundant ER-resident chaperone that has been shown to assist polypeptide maturation in the ER (Hendershot, 2004
). To compare kinetics of BiP association, lysis of cells expressing ectopic BACEs0, BACEs1, BACEs2, and BACEs4 was performed at the end of the chase times shown in Figures 3, A–D, in the presence of apyrase. Apyrase rapidly depletes cellular ATP and allows preservation of the noncovalent complexes engaging BiP and cellular substrates (Munro and Pelham, 1986
).
|
-glucosidases) and lectins (e.g., calnexin) may sterically interfere with BiP binding and/or may contribute to BiP displacement from newly synthesized polypeptides (see Discussion).
In the case of BACEs, it was not possible to prove or to exclude a sequential intervention of BiP and of the calnexin chaperone system. Sequential intervention of these two classes of chaperones was previously shown in the case of canonical ER-associated degradation (ERAD) substrates (Hebert and Molinari, 2007
and references therein). These are subjected to a first phase of "folding attempts" in the calnexin cycle from where they are subsequently extracted to be deviated into the BiP chaperone system and then degraded (reviewed in Olivari and Molinari, 2007
). It has also been possible to clearly distinguish two phases in which the BiP and the calnexin chaperone systems operate sequentially in the case of efficient folders such as viral gene products (Hebert and Molinari, 2007
and references therein). In the case of the proteins analyzed in this study, a fraction of the newly synthesized chains is subjected to productive folding, and a fraction fails to attain the native structure and is retained in the ER and eventually degraded. It is conceivable therefore, that the calnexin and the BiP chaperone systems act in parallel (rather than sequentially) on different populations of newly synthesized BACEs molecules.
An Inverse Correlation between Extent of BACEs Glycosylation and Formation of Detergent-soluble and -insoluble Aggregates
N-glycosylation determines the fate of the associated polypeptide chain in many different ways (Molinari, 2007
). The highly hydrophilic N-glycans enhance solubility of intermediates of the folding process and allow entry of nascent chains into the calnexin chaperone system. Significantly, separation of the glycosylation mutants in nonreducing gels (Figures 3, F–I) revealed that the extent of glycosylation inversely correlated with the propensity of a given model polypeptide to form aberrant, high-molecular-weight disulfide-bonded aggregates (DBA).
For BACEs0, only a fraction of the labeled protein entered the running gel and was separated in few intermediates of the oxidative BACEs0 folding program (folding intermediates [FI], Figure 3F, nonreducing). A substantial amount of the labeled protein progressively entered in complexes that remained at the interface between stacking and running gel when the samples were separated under nonreducing conditions (Figure 3F, DBA). After a 240 min of chase, the vast majority of labeled BACEs0 was in DBA (Figure 3F, nonreducing). Under reducing conditions, the BACEs0-containing, high-molecular-weight complexes were disassembled, confirming that they were disulfide-bonded aggregates (Figure 3F, reducing). Formation of disulfide-bonded aggregates is symptom of extensive protein misfolding and explains both the long intracellular persistence of BACEs0 (Figure 1B, intracellular) as well as the low secretion efficiency (Figure 1B, secreted, and Figure 1G). Only a minor fraction of labeled BACEs1 and s2 was trapped in disulfide-bonded aggregates (DBA in Figure 3, G and H, respectively), whereas aggregates were virtually absent in the case of BACEs4 (Figure 3I, DBA), consistent with the higher folding efficiency and secretion yield of the glycosylated variants of BACEs.
Solubilization of cells with CHAPS allows the separation of a soluble fraction, from which proteins are immunoisolated with specific antibodies as done for the figures shown so far and of a detergent-insoluble fraction. CHAPS-insoluble proteinaceous aggregates were dissolved by boiling the pellet of the CHAPS solubilization in 1% SDS. Subsequent immunoisolations with the BACEs-specific antibody were performed upon sample dilution with 10 volumes of 1% Triton X-100 to visualize the fraction of labeled, extensively misfolded, insoluble BACEs. Consistent with the data shown in Figure 3, F–I, a substantial amount of BACEs0 (20% of the synthesized protein) remained as insoluble material throughout the chase (Figure 3J, lanes 1 and 2). A fraction of the labeled glycosylated variants BACEs1 and BACEs3 was detergent-insoluble immediately after synthesis (Figure 3J, lanes 3 and 5, respectively). At longer chase times, however, the entire population of glycosylated BACEs was soluble in CHAPS (Figure 3J, lanes 4 and 6).
To summarize, the extent of BACEs glycosylation correlates directly with rate and efficiency of secretion and inversely with the propensity of the model protein to form detergent-soluble and -insoluble aggregates in association with BiP.
Blocking Substrate Release from Calnexin Differently Affects Secretion of BACEs Glycosylation Mutants
Most, if not all, newly synthesized glycoproteins expressed in the mammalian ER attain their native structure within the calnexin chaperone system. Substrate association with calnexin is mediated by mono-glucosylated N-glycans transiently displayed by nascent and newly synthesized polypeptides (Hammond et al., 1994
). The association signal is generated by the coordinated action of two ER-resident glycanases, the
-glucosidase I and the
-glucosidase II. They sequentially remove two of the three glucose residues from the polypeptide-bound oligosaccharide branch A. On substrate release from calnexin, removal of the third glucose residue by
-glucosidase II is required to prevent immediate substrate reassociation with calnexin. Calnexin interactions with glycopolypeptides are normally investigated by coimmunoprecipitation (Hammond et al., 1994
). This is a reliable assay for multiglycosylated polypeptides, but interactions of mono- or di-glycosylated polypeptides with calnexin are often lost during processing of the samples possibly generating false negatives. To circumvent this technical issue, we coupled conventional coimmunoprecipitation with a second assay in which we monitored variations in polypeptide secretion under conditions in which substrate association with calnexin progressed normally, but release was inhibited. To this end, cells expressing the five BACEs glycosylation mutants were exposed to the
-glucosidase inhibitor N-butyl-deoxynojirimycin (bDNJ) a few minutes after the pulse with radioactivity. Posttranslational addition of bDNJ does not affect the removal of the two outermost glucose residues, which allows entry of nascent polypeptides into the calnexin chaperone system. Rather, it substantially inhibits the glucosidase II-operated de-glucosylation of labeled glycoproteins, which is required for their efficient release from calnexin (Hebert et al., 1995
). We anticipated that this treatment would substantially decrease secretion of those mutants that associate with calnexin during maturation (please note that soluble variants of BACE do not associate with calreticulin;Pieren et al., 2005
and unpublished data). Cells were pulsed with radioactivity as described above and were chased for 5 min to allow BACEs association with calnexin. Incubation was prolonged to 120 min in the absence (– in Figure 4) or in the presence of bDNJ to inhibit substrate release from the chaperone (+ in Figure 4).
|
, X shows the calculated mobility of BACEs0, Figure 4A, lane 1). This was expected because N-glycans are required for substrate association with calnexin (Ou et al., 1993
Analysis of intracellular (Figure 4B, lanes 1 and 2) and of secreted BACEs0 (Figure 4B, lane 4) confirmed the disappearance of the labeled polypeptide from cells and the secretion of
4% of the labeled protein after 120 min of chase as shown in Figure 1. bDNJ treatment did not modify the intracellular content (Figure 4B, lane 3) and the amount of secreted BACEs0 (lane 5) as expected for a nonglycosylated polypeptide that does not associate with calnexin.
Similarly to the nonglycosylated variant, the mono-glycosylated BACEs1 did not coprecipitate with calnexin (Figure 4C). In this case, however, lack of coprecipitation must be ascribed to a disassembly of the BACEs1:calnexin complex during processing of the samples, as explained above. Analysis of the polypeptide fate, in fact, revealed that inhibition of substrates release from calnexin caused intracellular accumulation of labeled BACEs1 (compare lane 3 vs. lane 2 in Figure 4D) and a corresponding reduction of the polypeptide secretion by half from almost 30% of the total protein in untreated cells (Figures 4D, lane 4, and 1C, lane 10) to
15% in bDNJ treated cells after 120 min (Figure 4D, lane 5). The case of BACEs1 is relevant because there is some confusion in the literature on whether the single oligosaccharide displayed on mono-glycosylated polypeptides is or is not de-glucosylated by the
-glucosidase II to generate the mono-glucosylated trimming intermediate required to associate with calnexin (Deprez et al., 2005
; Totani et al., 2006
; Wilkinson et al., 2006
). Our data show that despite the technical difficulty to coprecipitate BACEs1 with calnexin (Figure 4C), this protein actually recruits the calnexin chaperone system where it remains trapped when de-glucosylation is inhibited (Figure 4D). Thus,
-glucosidase II generates mono-glucosylated trimming intermediate in vivo even in proteins displaying a single N-glycan.
The action of the ER-resident
-glucosidase II on mono-glycosylated polypeptides was confirmed in another cell type, namely Chinese hamster ovary cells (CHO). CHO lack a Golgi-resident endo-
-D-mannosidase that de-mannosylates polypeptides released from the ER with terminal glucoses on the oligosaccharide branch A (Hiraizumi et al., 1993
). In these cells, only if de-glucosylation in the ER progresses normally, oligosaccharides are processed by Golgi enzymes to complex structures that cannot be cleaved by EndoH (Rothman et al., 1984
; Lubas and Spiro, 1987
; Moore and Spiro, 1990
; Hiraizumi et al., 1993
). Analysis of the BACEs1 secreted from CHO cells confirmed that this mono-glycosylated protein had attained an EndoH-resistant status. In fact, the electrophoretic mobility of the mock-treated (Figure 4E, lane 1) and of the EndoH-treated polypeptide (lane 2) was the same. As a control, glycans displayed on secreted BACEs1 remained EndoH sensitive, and the labeled polypeptide showed faster electrophoretic mobility upon EndoH treatment (compare lanes 3 and 4 in Figure 4E), when ER-glucosidase activity was inhibited by cell incubation with bDNJ. Thus, mono-glycosylated polypeptides are de-glucosylated by
-glucosidases and enter in the calnexin chaperone system in vivo, even though substrate association with calnexin cannot directly be monitored by coprecipitation.
Coprecipitation with calnexin was observed for di-glycosylated BACEs2 (Figure 4F), showing that two N-glycans are sufficient for preserving the substrate chaperone complex during isolation. Analysis of the cell extracts and of the secreted material confirmed that inhibition of substrate release from calnexin resulted in intracellular retention (Figure 4G, compare lane 3 vs. 2) and impaired secretion of BACEs2 (lane 5 vs. 4). Similarly, bDNJ treatment inhibited both release from calnexin and secretion of BACEs3 (Figure 4, H–I) and BACEs4 (Figure 4, J–K). Thus, analysis of the intracellular protein retention and of the secretion in the extracellular media revealed that all variants displaying at least one N-glycan entered the calnexin chaperone system. Inhibition of substrate release from calnexin variably affected secretion of the individual mutants (Figure 4L, quantification of three independent experiments).
Inhibiting Substrate Association with Calnexin Differently Affects Secretion of BACEs Glycosylation Mutants
Next, we determined for each glycosylation variant the importance of folding in the calnexin chaperone system to attain a transport-competent conformation. To this end, cells were incubated in the presence of 1 mM bDNJ during starvation, pulse, and chase to preserve all N-glycans in the triglucosylated form that prevents substrate association with calnexin (Hammond et al., 1994
).
As expected, secretion of BACEs0, which is not glycosylated and does not associate with calnexin, was not affected by cell exposure to bDNJ (Figure 5A). All other glycosylation mutants showed a significant reduction of secretion efficiency in cells treated with the specific
-glucosidase inhibitor (Figure 5, B–E, and quantifications of three independent experiments in Figure 5F). Notably, secretion of BACEs1, which cannot be coimmunoisolated with calnexin (Figure 4C), was also substantially reduced when access into the calnexin chaperone system was inhibited (Figure 5B). Some confusion does exist on this issue in the available literature (Deprez et al., 2005
; Totani et al., 2006
; Wilkinson et al., 2006
). Our data clearly show that polypeptides displaying a single N-glycan are efficiently processed by ER
-glucosidases and attain a transport-competent conformation in association with calnexin. Surprisingly, inactivation of the calnexin cycle affects more dramatically the secretion of BACEs1 (fivefold reduction) and of BACEs2 (6.5-fold reduction) than the secretion of the more extensively glycosylated variants BACEs3 (threefold reduction) and BACEs4 (3.7-fold reduction; Figure 5F). These data show that the presence of 3 and 4 N-glycans has, per se, a positive effect on folding even when access to the lectin chaperone system is inhibited. By substantially increasing the hydrophilic surface, extensive glycosylation certainly reduces the propensity to enter in hydrophobic contacts with other unfolded chains that would irreversibly deviate the newly synthesized polypeptide into off pathways of the folding program.
|
Secretion efficiency for the BACEs proteins analyzed in this study ranged from 60% for the normally glycosylated polypeptide to
5% for the nonglycosylated variant. The secretion-deficient glycosylation mutants were retained intracellularly and/or degraded.
To assess whether BACEs productivity was improved by inhibition of ERAD, secretion of the 5 BACEs variants was compared in cells mock-treated or treated during the chase with PS-341 (Velcade), a cell permeable tripeptide (Pyrazylcarbonyl-Phe-Leu-boronate) used as therapeutic agent for relapsed multiple myeloma (Adams and Kauffman, 2004
). The boron atom of PS-341 binds the active site of the 26S proteasome, thereby specifically inhibiting proteasomal activity (Adams and Kauffman, 2004
).
Cells were incubated for 2 h and 30 min without (– in Figure 6, A–E) or with PS-341 (+ in Figure 6, A–E). Cell lysates were separated by SDS-PAGE and transferred to PVDF membranes. The membranes were probed with anti-ubiquitin antibodies to confirm proteasome inhibition and accumulation of poly-ubiquitylated polypeptides (poly-ub, Figure 6, A–E). The proteins in the extracellular media were also separated electrophoretically and transferred on PVDF membranes. These membranes were probed with the antibody to BACE to visualize the BACEs variants secreted from mock-treated cells (–) and from cells incubated with PS-341 (+).
|
| DISCUSSION |
|---|
|
|
|---|
The data show that the number of glycans displayed on BACEs correlated directly with rate and efficiency of polypeptide folding and secretion (Figures 1
–3) and that one N-linked glycan was sufficient to recruit the calnexin chaperone system and/or to allow substrate de-glucosylation by the ER-resident
-glucosidase II (Figures 4 and 5). This latter finding merits a specific comment. It is well known that substrate association with calnexin is very weak (Kapoor et al., 2003
). A direct and transient interaction can reliably be monitored by coimmunoprecipitation of multi-glycosylated substrates with the lectin chaperone, whereas for mono- and even for di-glycosylated polypeptides association might be lost during sample processing. Moreover, in isolated microsomes, the ER
-glucosidase II can only very inefficiently generate the mono-glucosylated trimming intermediate of the N-glycan processing reaction that allows association of a mono-glycosylated arrested chain with calnexin (Deprez et al., 2005
). How and if mono-glycosylated polypeptides make use of the calnexin chaperone system is therefore unclear (Deprez et al., 2005
; Totani et al., 2006
; Wilkinson et al., 2006
). By coupling conventional coimmunoprecipitation with two assays in which we monitored variations in polypeptide secretion under conditions in which substrate association or release from calnexin were inhibited, our data convincingly show that mono-glycosylated polypeptides gain access to the calnexin system in living cells. The variants with 1 and 2 N-glycans actually suffered much more than the variants with 3 and 4 N-glycans upon inactivation of the calnexin chaperone system (Figure 5). Thus, hyper-glycosylation per se enhances the protein folding process, even in the absence of lectin assistance, possibly by preventing entry in off pathways of the polypeptide's folding program. Consistently, the number of glycans correlated inversely with the propensity of the polypeptide chain to enter in detergent-soluble or -insoluble aggregates (Figure 3).
Stepwise addition of N-glycans also correlated with a progressive increase in the rate of substrate release from BiP (Figure 3). This finding implies that not only chaperone selection (Molinari and Helenius, 2000
), but also substrate release from specific chaperone machineries could be dictated by competition with other chaperones willing to act on the newly synthesized chain. In the specific case, we propose that the intervention of sugar processing enzymes (
-glucosidases) and lectins (e.g., calnexin) may contribute to BiP displacement from newly synthesized, folding polypeptides. An alternative explanation is that the faster release from BiP derives from an acceleration of the folding process that rapidly conceals binding determinants for this conventional chaperone, independent of the steric hindrance caused by the intervention of other chaperones to assist the maturation of the folding polypeptides.
Finally, one should notice that there is a good correlation between the kinetics of attainment of DTT-resistant structures and the rate of secretion of the individual BACEs variants (Figures 1 and 2). However, for none of the BACEs variants, the entire population of DTT-resistant conformers was secreted from cells as active enzyme. For example, the fraction of intracellular DTT-resistant BACEs0 reaches the 20% of the labeled protein, but not more than the 5% of it is actually secreted. This may indicate that only a fraction of the DTT-resistant conformers actually have native structure. Alternatively, or in addition to that, it is conceivable that the retention-based quality control operating in the ER is too stringent and inhibits export of a fraction of native (DTT-resistant) BACEs conformers. This implies that the manipulation of the ER quality control tightness or the intervention on the relative activities of the folding versus ERAD machineries operating in cells expressing ectopic proteins may offer an interesting opportunity to enhance productivity of functional polypeptides (Figure 6). Consistently, and similarly to what reported for folding-defective proteins such as mutated CFTR and dystrophin (Bonuccelli et al., 2003
; Farinha and Amaral, 2005
; Vij et al., 2006
), proteasome inhibition increased the yield of active BACEs harvested from the cell culture media. In most of the cases, inactivation of the proteasome inhibits translocation of proteins from the ER lumen into the cytosol (reviewed in Hebert and Molinari, 2007
). It is therefore likely that in the presence of proteasome inhibitors polypeptides that are inappropriately deviated into the degradation machinery at steady state are allowed to spend longer time in the ER lumen, thus eventually escaping aberrant retention by the quality control machinery.
It should be noted that, even a modest increase of the fraction of a mutated protein terminating the folding program as an active entity may considerably reduce the course of loss-of-function disorders caused by premature polypeptide disposal (Aridor, 2007
; Hebert and Molinari, 2007
). A 20–30% increase in the yield of active recombinant proteins may also offer a significant economic interest for industrial production of biomolecules (Baldi et al., 2007
).
| ACKNOWLEDGMENTS |
|---|
| Footnotes |
|---|
Address correspondence to: Maurizio Molinari (maurizio.molinari{at}irb.unisi.ch)
Abbreviations used: BACE, Beta-site APP-cleaving enzyme 1; BACEs, soluble form of BACE; bDNJ, N-butyl-deoxynojirimycin; CHO, Chinese hamster ovary cells; DBA, disulfide-bonded aggregates; EndoH, endoglycosidase H; ER, endoplasmic reticulum; ERAD, ER-associated degradation; HEK, human embryonic kidney cells.
| REFERENCES |
|---|
|
|
|---|
Aridor, M. (2007). Visiting the ER: the endoplasmic reticulum as a target for therapeutics in traffic related diseases. Adv. Drug Deliv. Rev 59, 759–781.[CrossRef][Medline]
Baldi, L., Hacker, D. L., Adam, M., and Wurm, F. M. (2007). Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol. Lett 29, 677–684.[CrossRef][Medline]
Blond-Elguindi, S., Cwirla, S. E., Dower, W. J., Lipshutz, R. J., Sprang, S. R., Sambrook, J. F., and Gething, M. J. (1993). Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP. Cell 75, 717–728.[CrossRef][Medline]
Bonuccelli, G., Sotgia, F., Schubert, W., Park, D. S., Frank, P. G., Woodman, S. E., Insabato, L., Cammer, M., Minetti, C., and Lisanti, M. P. (2003). Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am. J. Pathol 163, 1663–1675.
Caramelo, J. J., and Parodi, A. J. (2007). How sugars convey information on protein conformation in the endoplasmic reticulum. Semin. Cell Dev. Biol 18, 732–742.[CrossRef][Medline]
Caramelo, J. J., and Parodi, A. J. (2008). Getting in and out from calnexin/calreticulin cycles. J. Biol. Chem 283, 10221–10225.
Deprez, P., Gautschi, M., and Helenius, A. (2005). More than one glycan is needed for ER glucosidase II to allow entry of glycoproteins into the calnexin/calreticulin cycle. Mol. Cell 19, 183–195.[CrossRef][Medline]
Ellgaard, L., Molinari, M., and Helenius, A. (1999). Setting the standards: quality control in the secretory pathway. Science 286, 1882–1888.
Farinha, C. M., and Amaral, M. D. (2005). Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol. Cell. Biol 25, 5242–5252.
Hammond, C., Braakman, I., and Helenius, A. (1994). Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc. Natl. Acad. Sci. USA 91, 913–917.
Hebert, D. N., Foellmer, B., and Helenius, A. (1995). Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell 81, 425–433.[CrossRef][Medline]
Hebert, D. N., Garman, S. C., and Molinari, M. (2005). The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends Cell Biol 15, 364–370.[CrossRef][Medline]
Hebert, D. N., and Molinari, M. (2007). In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev 87, 1377–1408.
Hendershot, L. M. (2004). The ER function BiP is a master regulator of ER function. Mt. Sinai. J. Med 71, 289–297.[Medline]
Hiraizumi, S., Spohr, U., and Spiro, R. G. (1993). Characterization of endomannosidase inhibitors and evaluation of their effect on N-linked oligosaccharide processing during glycoprotein biosynthesis. J. Biol. Chem 268, 9927–9935.
Hong, L., Koelsch, G., Lin, X., Wu, S., Terzyan, S., Ghosh, A. K., Zhang, X. C., and Tang, J. (2000). Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290, 150–153.
Kapoor, M., Srinivas, H., Kandiah, E., Gemma, E., Ellgaard, L., Oscarson, S., Helenius, A., and Surolia, A. (2003). Interactions of substrate with calreticulin, an endoplasmic reticulum chaperone. J. Biol. Chem 278, 6194–6200.
Kopito, R. R. (1999). Biosynthesis and degradation of CFTR. Physiol. Rev 79, S167–S173.[Medline]
Lederkremer, G. Z., and Glickman, M. H. (2005). A window of opportunity: timing protein degradation by trimming of sugars and ubiquitins. Trends Biochem. Sci 30, 297–303.[CrossRef][Medline]
Lubas, W. A., and Spiro, R. G. (1987). Golgi endo-alpha-D-mannosidase from rat liver, a novel N-linked carbohydrate unit processing enzyme. J. Biol. Chem 262, 3775–3781.
Meusser, B., Hirsch, C., Jarosch, E., and Sommer, T. (2005). ERAD: the long road to destruction. Nat. Cell Biol 7, 766–772.[CrossRef][Medline]
Molinari, M. (2007). N-glycan structure dictates extension of protein folding or onset of disposal. Nat. Chem. Biol 3, 313–320.[CrossRef][Medline]
Molinari, M., and Helenius, A. (2000). Chaperone selection during glycoprotein translocation into the endoplasmic reticulum. Science 288, 331–333.
Moore, S. E., and Spiro, R. G. (1990). Demonstration that Golgi endo-alpha-D-mannosidase provides a glucosidase-independent pathway for the formation of complex N-linked oligosaccharides of glycoproteins. J. Biol. Chem 265, 13104–13112.
Munro, S., and Pelham, H. R. (1986). An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 46, 291–300.[CrossRef][Medline]
Nakatsukasa, K., and Brodsky, J. L. (2008). The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. Traffic 9, 861–870.[CrossRef][Medline]
Olivari, S., and Molinari, M. (2007). Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in degradation of folding-defective glycoproteins. FEBS Lett 581, 3658–3664.[CrossRef][Medline]
Ou, W. J., Cameron, P. H., Thomas, D. Y., and Bergeron, J. J. (1993). Association of folding intermediates of glycoproteins with calnexin during protein maturation. Nature 364, 771–776.[CrossRef][Medline]
Pearse, B. R., Gabriel, L., Wang, N., and Hebert, D. N. (2008). A cell-based reglucosylation essay demonstrates the role of GT1 in the quality control of a maturing protein. J. Cell Biol 181, 309–320.
Pieren, M., Galli, C., Denzel, A., and Molinari, M. (2005). The use of calnexin and calreticulin by cellular and viral glycoproteins. J. Biol. Chem 280, 28265–28271.
Rothman, J. E., Urbani, L. J., and Brands, R. (1984). Transport of protein between cytoplasmic membranes of fused cells: correspondence to processes reconstituted in a cell-free system. J. Cell Biol 99, 248–259.
Sardana, V., Xu, B., Zugay-Murphy, J., Chen, Z., Sardana, M., Darke, P. L., Munshi, S., and Kuo, L. C. (2004). A general procedure for the purification of human beta-secretase expressed in Escherichia coli. Protein Expr. Purif 34, 190–196.[CrossRef][Medline]
Shimizu, H., Tosaki, A., Kaneko, K., Hisano, T., Sakurai, T., and Nukina, N. (2008). Crystal structure of an active form of BACE1: an enzyme responsible for amyloid {beta} protein production. Mol. Cell. Biol 28, 3663–3671.
Soldà, T., Galli, C., Kaufman, R. J., and Molinari, M. (2007). Substrate-specific requirements for UGT1-dependent release from calnexin. Mol. Cell 27, 238–249.[CrossRef][Medline]
Tatu, U., Braakman, I., and Helenius, A. (1993). Membrane glycoprotein folding, oligomerization and intracellular transport: effects of dithiothreitol in living cells. EMBO J 12, 2151–2157.[Medline]
Thornton, J. M. (1981). Disulphide bridges in globular proteins. J. Mol. Biol 151, 261–287.[CrossRef][Medline]
Totani, K., Ihara, Y., Matsuo, I., and Ito, Y. (2006). Substrate specificity analysis of endoplasmic reticulum glucosidase II using synthetic high-mannose-type glycans. J. Biol. Chem 281, 31502–31508.
Vij, N., Fang, S., and Zeitlin, P. L. (2006). Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem 281, 17369–17378.
Wilkinson, B. M., Purswani, J., and Stirling, C. J. (2006). Yeast GTB1 encodes a subunit of glucosidase II required for glycoprotein processing in the endoplasmic reticulum. J. Biol. Chem 281, 6325–6333.
This article has been cited by other articles:
![]() |
T. Watanabe, K. Totani, I. Matsuo, J.-i. Maruyama, K. Kitamoto, and Y. Ito Genetic analysis of glucosidase II {beta}-subunit in trimming of high-mannose-type glycans Glycobiology, August 1, 2009; 19(8): 834 - 840. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||